Literature DB >> 9780533

A note on confidence intervals in cost-effectiveness analysis.

M Tambour1, N Zethraeus, M Johannesson.   

Abstract

How to obtain confidence intervals for cost-effectiveness ratios is complicated by the statistical problems of obtaining a confidence interval for a ratio of random variables. Different approaches have been suggested in the literature, but no consensus has been reached. We propose an alternative simple solution to this problem. By multiplying the effectiveness units by the price per effectiveness unit, both costs and benefits can be expressed in monetary terms and standard statistical techniques can be used to estimate a confidence interval for net benefits. This approach avoids the ratio estimation problem and explicitly recognizes that the price per effectiveness unit has to be known to provide cost-effectiveness analysis with a useful decision rule.

Mesh:

Year:  1998        PMID: 9780533     DOI: 10.1017/s0266462300011442

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  32 in total

Review 1.  Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio.

Authors:  A O'Hagan; J W Stevens; J Montmartin
Journal:  Pharmacoeconomics       Date:  2000-04       Impact factor: 4.981

Review 2.  Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies.

Authors:  Niklas Zethraeus; Magnus Johannesson; Bengt Jönsson; Mickael Löthgren; Magnus Tambour
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 3.  Sample size determination for cost-effectiveness trials.

Authors:  Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

4.  Choice of statistical model for cost-effectiveness analysis and covariate adjustment: empirical application of prominent models and assessment of their results.

Authors:  Theodoros Mantopoulos; Paul M Mitchell; Nicky J Welton; Richard McManus; Lazaros Andronis
Journal:  Eur J Health Econ       Date:  2015-10-07

5.  Lessons from trial-based cost-effectiveness analyses of mental health interventions: why uncertainty about the outcome, estimate and willingness to pay matters.

Authors:  Jeffrey S Hoch; Carolyn S Dewa
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

6.  Bridging the gap between health and non-health investments: moving from cost-effectiveness analysis to a return on investment approach across sectors of economy.

Authors:  Pedram Sendi
Journal:  Int J Health Care Finance Econ       Date:  2008-03-20

7.  Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme.

Authors:  Janne A Martikainen; Akseli Kivioja; Taru Hallinen; Pia Vihinen
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

8.  Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach.

Authors:  Annemieke De Ridder; Diana De Graeve
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 9.  Use of Claims Data for Cost and Cost-Effectiveness Research.

Authors:  Ya-Chen Tina Shih; Lei Liu
Journal:  Semin Radiat Oncol       Date:  2019-10       Impact factor: 5.934

10.  Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.

Authors:  Ya-Chen Tina Shih; Nebiyou B Bekele; Ying Xu
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.